Evocalcet

SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS

Key facts

Evocalcet is a drug catalogued in DrugCentral. It was first approved by the PMDA in 2018. DrugCentral lists 1 molecular target, including CASR. Recorded indications include Hypercalcemia in parathyroid carcinoma, Hypercalcemia in primary hyperparathyroidism and Secondary hyperparathyroidism.

• Molecular targets: CASR (1 listed in DrugCentral).
• Indications: Hypercalcemia in parathyroid carcinoma, Hypercalcemia in primary hyperparathyroidism and Secondary hyperparathyroidism.
• ATC code: H05BX06 (Other anti-parathyroid agents).
• Molecular formula: C24H26N2O2; molecular weight 374.48 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (3)

• Hypercalcemia in parathyroid carcinoma
• Hypercalcemia in primary hyperparathyroidism
• Secondary hyperparathyroidism

Mechanism & targets

Molecular targets (1)

Target	Gene	Action	Activity
Extracellular calcium-sensing receptor	CASR	agonist	EC50 7.03

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2018-03-23	PMDA	—	Kyowa Hakko Kirin Co., Ltd.

ATC classification

ATC code	Therapeutic hierarchy
H05BX06	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS › CALCIUM HOMEOSTASIS › ANTI-PARATHYROID AGENTS › Other anti-parathyroid agents

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Shunt stenosis	150.3
Shunt occlusion	95.4

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Evocalcet is on its molecule page.

• Molecular formula: C₂₄H₂₆N₂O₂
• Molecular weight: 374.48 g/mol
• CAS number: 870964-67-3
• InChIKey: RZNUIYPHQFXBAN-XLIONFOSSA-N
• PubChem CID: 71242808

C[C@@H](N[C@H]1CCN(C1)C1=CC=C(CC(O)=O)C=C1)C1=CC=CC2=CC=CC=C12

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Evocalcet used for?

DrugCentral lists the following indications for Evocalcet: Hypercalcemia in parathyroid carcinoma, Hypercalcemia in primary hyperparathyroidism and Secondary hyperparathyroidism.

How does Evocalcet work?

Its molecular targets in DrugCentral include CASR (agonist).

When was Evocalcet first approved?

Evocalcet was first approved by the PMDA in 2018.

What is the chemical formula of Evocalcet?

Evocalcet has the molecular formula C24H26N2O2 and a molecular weight of 374.48 g/mol.

Sources

• DrugCentral drug card 5307 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL4297621 — compound record and bioactivity
• PubChem CID 71242808 — chemical identifiers
• DrugBank DB12388 — drug record
• FDA UNII E58MLH082P — substance identity
• UniProt P41180 (CASR) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.